December 12th 2024
The companies will develop a platform that can enable rapid development of DPI products.
November 20th 2024
Therapeutic Delivery for Brain-Related Conditions
June 14th 2024At BIO 2024 in San Diego, John Dunlop, PhD, chief scientific officer at Aliada Therapeutics, sat down for an interview with BioPharm International to discuss the firm’s MODEL platform and its potential impact on therapeutic delivery for brain-related conditions.
BenevolentAI Signs Collaboration with Merck
September 26th 2023BenevolentAI will leverage its suite of AI chemistry design tools in combination with its fully equipped wet lab facility in Cambridge, UK, to deliver small molecule drug development candidates into the Merck pipeline, according to the press release.
Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone
September 25th 2023The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.
CPHI Annual Report Predicts AI Transformation of All Drug Development Processes by 2026
September 15th 2023AI’s role in target discovery and manufacturing optimization remained the most chosen application looking three years ahead; however, approximately 43% envision that it will help to build base regulatory submissions.
Apollo Therapeutics Closes $226.5 Million Series C Financing
September 15th 2023Apollo is a part of a research and development platform for the development of new medicines, with program selection being hesitant to indication and primarily driven by quality of science or the potential to transform the standard of care in major commercial markets, according to the press release.
Ono Pharmaceutical Enters Drug Discovery Collaboration Agreement with Twist Bioscience
August 31st 2023Twist Bioscience is a synthetic biology and genomics company that has developed a DNA synthesis platform to industrialize the engineering of biology, which is a new method of this process by “writing” DNA on a silicon chip.